News | December 13, 2025
EMA backs Eylea 8 mg for retinal vein occlusion
The positive CHMP opinion is supported by results from the Phase III QUASAR trial
The positive CHMP opinion is supported by results from the Phase III QUASAR trial
The new centre brings advanced corneal procedures pioneered in India
This partnership strengthens LMS as a leading CDMO supplier of peptide materials for both innovator and generic markets
This is the first approval of a prescription transdermal dosage Form in the European markets from this facility
India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
This strategic investment aims to bolster the company's position as a global leader in Vitamin D3 manufacturing
Expands bioprocessing footprint across Asia
The collaboration will establish the MUMPMP–Agilent BioDiscovery Hub
While Merck can appeal, Halozyme said it expects the order to hold
The launch of the study was on the occasion of the International Day of Persons with Disabilities
Subscribe To Our Newsletter & Stay Updated
